PMID: 9432032Jan 31, 1998Paper

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group

British Journal of Haematology
E VandenbergheD C Linch

Abstract

Mantle cell lymphoma (MCL) was first described as a distinct biological entity on the basis of its association with the t(11;14)(q13;q32) resulting in over-expression of the cyclin D1 gene. Recognition of the morphological, immunophenotypic and clinical characteristics of MCL has enabled the accurate diagnosis of this entity and appreciation of its poor prognosis. Most published series of patients with MCL have used anthracycline-containing regimens. In contrast the British National Lymphoma Investigation (BNLI) group have treated 65 patients with MCL with non-intensive 'low-grade lymphoma' therapy. The median overall survival of 57 months and progression-free survival of 24 months compares favourably with the more intensively treated series. Although the disease was generally more aggressive than other low-grade lymphomas, some patients were asymptomatic and had indolent disease. When compared to 1853 patients with non-MCL low-grade lymphomas entered on the BNLI database, patients were found on average to be older (P=0.02), to have more extranodal disease (P<0.00001), and a higher proportion to have a raised ESR (P=0.02) and a low serum albumin (P=0.002). Multivariate analysis of significant prognostic markers in all BNLI low-...Continue Reading

Citations

Jul 18, 2003·Lancet·Linda S Evans, Barry W Hancock
Mar 21, 2002·The Lancet Oncology·I BaristaF Cabanillas
Apr 16, 2002·European Journal of Haematology·Maria K AngelopoulouGerassimos A Pangalis
Sep 27, 2006·The American Journal of Surgical Pathology·Antonio SalarSergio Serrano
Jun 8, 2006·International Journal of Hematology·Naoto TomitaKengo Takeuchi
Sep 29, 2005·Hematology·Gerassimos A PangalisPanayiotis Panayiotidis
Aug 27, 2005·Expert Opinion on Biological Therapy·Samuel A Jacobs, Kenneth A Foon
Jun 11, 2011·Critical Reviews in Oncology/hematology·Sergio CortelazzoMartin Dreyling
Oct 18, 2005·British Journal of Haematology·Deborah BauwensEric Van Den Neste
Aug 22, 2009·British Journal of Haematology·Saar GillJohn F Seymour
Nov 28, 2008·British Journal of Haematology·Mars B van 't VeerWim L J van Putten
Sep 22, 2012·British Journal of Haematology·P McKayUNKNOWN British Committee for Standards in Haematology
Oct 19, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·C W TipladyUNKNOWN Scotland and Newcastle Lymphoma Group
Jun 15, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Lisa LowryPeter Hoskin
Mar 8, 2005·Blood Reviews·Maher K Gandhi, Robert E Marcus
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter MartinJohn P Leonard
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Orion M HowardMargaret A Shipp
Jun 14, 2017·Nature Reviews. Clinical Oncology·Joel CunninghamBhupinder Sharma
Sep 14, 2006·Virchows Archiv : an International Journal of Pathology·Miltiadis AspiotisMaria Bai
May 17, 2018·British Journal of Haematology·Pamela McKaySimon Rule
Jan 8, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N GersonStefan K Barta
Jun 21, 2019·Current Hematologic Malignancy Reports·James N Gerson, Stefan K Barta
Aug 30, 2013·Experimental Biology and Medicine·Steve A Maxwell, Seyed Mousavi-Fard
Aug 31, 2020·Hematology/oncology Clinics of North America·Jason T Romancik, Jonathon B Cohen
Jun 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B S KahlUNKNOWN Wisconsin Oncology Network

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
R OinonenE Elonen
Nature Clinical Practice. Oncology
Antonio J Grillo-López
© 2021 Meta ULC. All rights reserved